Rchr
J-GLOBAL ID：202101004930812330
Update date: Dec. 17, 2023
Fujimoto Kenji
Fujimoto Kenji
Affiliation and department：
Research field (3)：
Tumor biology
, Neurosurgery
, Genomics
Research keywords (3)：
小児脳腫瘍
, 中枢神経原発悪性リンパ腫
, グリオーマ
Research theme for competitive and other funds (3)：
- 2022 - 2025 メソトレキサート耐性中枢神経原発悪性リンパ腫に対する新規治療標的の探索
- 2019 - 2023 悪性脳腫瘍におけるポリグルタミル化制御による新規治療法の開発
- 2021 - 2023 New ependymoma modeling approaches
Papers (16)：
-
Kaishi Satomi, Akihiko Yoshida, Yuko Matsushita, Hirokazu Sugino, Kenji Fujimoto, Mai Honda-Kitahara, Masamichi Takahashi, Makoto Ohno, Yasuji Miyakita, Yoshitaka Narita, et al. Clinical application of a highly sensitive digital PCR assay to detect a small fraction of IDH1 R132H-mutant alleles in diffuse gliomas. Brain tumor pathology. 2022. 39. 4. 210-217
-
Kenji Fujimoto, Hideyuki Arita, Kaishi Satomi, Kai Yamasaki, Yuko Matsushita, Taishi Nakamura, Yasuji Miyakita, Toru Umehara, Keiichi Kobayashi, Kaoru Tamura, et al. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma. Acta neuropathologica. 2021. 142. 2. 323-338
-
Histone deacetylase inhibition enhances the therapeutic effects of methotrexate on primary central nervous system lymphoma. Neuro-oncology advances. 2020. 2. 1
-
Kensuke Tateishi, Taishi Nakamura, Tareq A Juratli, Erik A Williams, Yuko Matsushita, Shigeta Miyake, Mayuko Nishi, Julie J Miller, Shilpa S Tummala, Alexandria L Fink, et al. PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019. 25. 14. 4375-4387
-
Masamichi Takahashi, Shunichiro Miki, Kenji Fujimoto, Kohei Fukuoka, Yuko Matsushita, Yoshiko Maida, Mami Yasukawa, Mitsuhiro Hayashi, Raku Shinkyo, Kiyomi Kikuchi, et al. Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts. Cancer science. 2019. 110. 7. 2247-2257
ｍore...
MISC (28)：
-
牧野敬史, 黒田順一郎, 藤本健二, 上田隆太, 高田明, 武笠晃丈. Evaluation of treatment results of total cranial remodeling for Scaphocephaly. 小児の脳神経. 2021. 46. 2
-
篠島直樹, 伊東山剛, 山本隆広, 牧野敬史, 藤本健二, 黒田順一郎, 武笠晃丈. Trends in pediatric brain tumors in Kumamoto Prefecture. 小児の脳神経. 2020. 45. 3
-
牧野敬史, 藤本健二, 高田明, 武笠晃丈. Clinical characteristics of radiation related stroke in two cases with malignant brain tumor. 小児の脳神経. 2020. 45. 3
-
藤本健二, 藤本健二, 藤本健二, 有田英之, 有田英之, 金村米博, 田中將太, 永根基雄, 植木敬介, 西川亮, et al. IDH wildtype LGGにおける最も重要な予後不良因子はTERT promoter mutationである. Brain Tumor Pathology (Web). 2020. 37. Supplement
-
篠島直樹, 藤本健二, 山本隆広, 大田和貴, 竹崎達也, 黒田順一郎, 牧野敬史, 武笠晃丈. The future direction of treatment development for primary central nervous system lymphoma (PCNSL). 日本脳腫瘍学会プログラム・抄録集. 2020. 38th
ｍore...
Professional career (1)：
- M.D, Ph.D. (Kumamoto University)
Awards (1)：
- 2022/12 - 日本脳腫瘍学会 第30回星野賞
Return to Previous Page
